March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Primary Results Of Recombinant Vascular Endothelial Growth Factor Receptor-antibody Fusion Protein For Diabetic Macular Edema
Author Affiliations & Notes
  • Kun Liu
    Ophthalmology, The first peole's hospital affilated to SJTU, Shanghai, China
  • Xun Xu
    Ophthalmology, The first peole's hospital affilated to SJTU, Shanghai, China
  • Delun Luo
    Chengdu Kanghong Biological Science & Technology Co., Ltd, Chengdu, China
  • Xiao Ke
    Chengdu Kanghong Biological Science & Technology Co., Ltd, Chengdu, China
  • Footnotes
    Commercial Relationships  Kun Liu, None; Xun Xu, None; Delun Luo, None; Xiao Ke, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 402. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kun Liu, Xun Xu, Delun Luo, Xiao Ke; Primary Results Of Recombinant Vascular Endothelial Growth Factor Receptor-antibody Fusion Protein For Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2012;53(14):402.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy and safety of multiple intravitreal injection of recombinant vascular endothelial growth factor receptor-antibody fusion protein (KH902) for diabetic macular edema (DME).

Results: : twenty patients (Group A: 10, Group B: 10), including 9 males and 11 females, with mean age of 62.9 years had been enrolled. 16 patients had completed 3 months of core treatment (8 patients in A and B group each). Comparison of improvement in BCVA, CRT and CRV between baseline and after-core treatment showed increment of 7.85 letters in BCVA (58.00+12.39 vs 65.85+10.96), decrease of 94.23mm in CRT (436.46+94.23mm vs 345.29+49.92mm) and decrease of 0.07 mm3 in CRV (0.34+0.08mm3 vs 0.27+0.04mm3). Further analysis indicated that group A gained increment of 5.83 letters in BCVA (57.00+5.06 vs 62.83+6.05), decrease of 95.33mm and 0.08 mm3 in CRT (424.67+106.28mm vs 329.33 +47.81mm) and CRV (0.34+0.08mm3 vs 0.26+0.04mm3), respectively, and that, for B group, increment of 9.57letters in BCVA (58.86+16.85vs 68.43+13.89), decrease of 86.43mm and 0.07mm3 in CRT (446.57+89.92mm vs 360.14+50.67mm) and CRV (0.35+0.07mm3 vs 0.28+0.04mm3), respectively, were detected. 8 patients had completed one year follow-up. The changes between baseline and 12 month were as follows: increment of 6.13 letters in BCVA (55.63+13.82 vs 61.75+14.52), decrease of 128.50mm in CRT (450.25+88.96mm vs 321.75+40.08mm) and decrease of 0.10 mm3 in CRV (0.36+0.07mm3 vs 0.25+0.03mm3).There were some adverse events such as conjunctival hemorrhage due to intravitreal injection. No serious adverse events related to Kh902 so far.

Conclusions: : Multiple intravitreal injection of human recombinant vascular endothelial growth factor receptor-antibody fusion protein (KH902) could efficiently relieve the macular edema of DME patients and improve visual acuity. The preliminary clinical results provided basic data for further multi-center clinical trial in the future.

Clinical Trial: : http://www.clinicaltrials.gov NCT01324869

Keywords: diabetic retinopathy • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×